USPTO granted Tambo, Inc. Patent US12589162B2, titled 'Trans-cyclooctene prodrug of monomethyl auristatin E.' The patent covers a 6-(Carbonyloxy)-1-methylcyclooct-4-ene-1-carbonyl)-aspartic acid conjugate of monomethyl auristatin E for bioorthogonal delivery in treating cancer and tumor growths. The patent includes 4 claims and names Jose Manuel Mejia Oneto, Nathan A. Yee, and Jesse M. McFarland as inventors.

This patent grant provides Tambo, Inc. with market exclusivity for the specified compound and its cancer treatment applications through the patent term. Patent holders should maintain documentation of this grant and monitor for potential infringement. No specific compliance actions are required by other parties.